• Je něco špatně v tomto záznamu ?

Biological variation of intact fibroblast growth factor 23 measured on a fully automated chemiluminescent platform

A. Jabor, Z. Kubíček, J. Komrsková, T. Vacková, J. Vymětalík, J. Franeková,

. 2019 ; 56 (3) : 381-386. [pub] 20190227

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006562

BACKGROUND: Fibroblast growth factor 23 (FGF23), a potent regulator of phosphate and vitamin D metabolism, is a new biomarker of kidney, bone and cardiovascular disorders. The aim of this study was to assess the biological variation of intact fibroblast growth factor 23 (iFGF23). METHODS: The within-subject (CVI) and between-subject (CVG) biological variations were assessed in 14 healthy volunteers in a six-week protocol (seven samples). Imprecision (CVA) was assessed by duplicate measurements and the EP15-A2 protocol. Intact FGF23 was measured using a fully automated chemiluminescent assay (Liaison XL, DiaSorin S.p.A., Saluggia, Italy). Two methods with different sensitivities to non-Gaussian distribution were used to estimate the CVI, SD ANOVA and CV ANOVA methods. We calculated the index of individuality (II) and reference change values. RESULTS: Depending on the statistical method used, the CVI and CVA were 14.2 and 3.7% (SD ANOVA) or 12.5 and 3.9% (CV ANOVA), respectively. The corresponding reference change values were 40.5 and 36.4%, respectively. The CVG was 13.4% (SD ANOVA was the only option), and the total imprecision (EP15-A2) was less than 7%. CONCLUSIONS: The measurement of iFGF23 demonstrated a CVA less than 4% during the experimental estimation of biological variation. The total imprecision was less than 7% in the EP15-A2 experiment. The CVI values of iFGF23 in healthy persons were 14.2 (SD ANOVA) and 12.5% (CV ANOVA), respectively. The CVG was 13.4%, and the resulting index of individuality was 1.06. The reference change value was less than 41%. The availability of this automated assay for iFGF23 with well-characterized biological variation data delivers opportunities for improved availability and application of this assay clinically.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006562
003      
CZ-PrNML
005      
20210720101339.0
007      
ta
008      
200511s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/0004563219826161 $2 doi
035    __
$a (PubMed)30813741
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Jabor, Antonín $u 1 Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Praha, Czech Republic. 2 Third Faculty of Medicine, Charles University, Praha, Czech Republic.
245    10
$a Biological variation of intact fibroblast growth factor 23 measured on a fully automated chemiluminescent platform / $c A. Jabor, Z. Kubíček, J. Komrsková, T. Vacková, J. Vymětalík, J. Franeková,
520    9_
$a BACKGROUND: Fibroblast growth factor 23 (FGF23), a potent regulator of phosphate and vitamin D metabolism, is a new biomarker of kidney, bone and cardiovascular disorders. The aim of this study was to assess the biological variation of intact fibroblast growth factor 23 (iFGF23). METHODS: The within-subject (CVI) and between-subject (CVG) biological variations were assessed in 14 healthy volunteers in a six-week protocol (seven samples). Imprecision (CVA) was assessed by duplicate measurements and the EP15-A2 protocol. Intact FGF23 was measured using a fully automated chemiluminescent assay (Liaison XL, DiaSorin S.p.A., Saluggia, Italy). Two methods with different sensitivities to non-Gaussian distribution were used to estimate the CVI, SD ANOVA and CV ANOVA methods. We calculated the index of individuality (II) and reference change values. RESULTS: Depending on the statistical method used, the CVI and CVA were 14.2 and 3.7% (SD ANOVA) or 12.5 and 3.9% (CV ANOVA), respectively. The corresponding reference change values were 40.5 and 36.4%, respectively. The CVG was 13.4% (SD ANOVA was the only option), and the total imprecision (EP15-A2) was less than 7%. CONCLUSIONS: The measurement of iFGF23 demonstrated a CVA less than 4% during the experimental estimation of biological variation. The total imprecision was less than 7% in the EP15-A2 experiment. The CVI values of iFGF23 in healthy persons were 14.2 (SD ANOVA) and 12.5% (CV ANOVA), respectively. The CVG was 13.4%, and the resulting index of individuality was 1.06. The reference change value was less than 41%. The availability of this automated assay for iFGF23 with well-characterized biological variation data delivers opportunities for improved availability and application of this assay clinically.
650    _2
$a dospělí $7 D000328
650    _2
$a analýza rozptylu $7 D000704
650    _2
$a automatizace $7 D001331
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibroblastové růstové faktory $x analýza $7 D005346
650    _2
$a zdraví dobrovolníci pro lékařské studie $7 D064368
650    _2
$a lidé $7 D006801
650    _2
$a luminiscenční měření $x normy $7 D008163
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a referenční hodnoty $7 D012016
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kubíček, Zdenek, $u 1 Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Praha, Czech Republic. $d 1946- $7 jo2015865150
700    1_
$a Komrsková, Jitka $u 1 Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Praha, Czech Republic.
700    1_
$a Vacková, Tereza $u 1 Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Praha, Czech Republic.
700    1_
$a Vymětalík, Jiří $u 1 Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Praha, Czech Republic.
700    1_
$a Franeková, Janka $u 1 Department of Laboratory Methods, Institute for Clinical and Experimental Medicine, Praha, Czech Republic. 2 Third Faculty of Medicine, Charles University, Praha, Czech Republic.
773    0_
$w MED00000421 $t Annals of clinical biochemistry $x 1758-1001 $g Roč. 56, č. 3 (2019), s. 381-386
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30813741 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20210720101337 $b ABA008
999    __
$a ok $b bmc $g 1525420 $s 1096618
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 56 $c 3 $d 381-386 $e 20190227 $i 1758-1001 $m Annals of clinical biochemistry $n Ann Clin Biochem $x MED00000421
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace